422 related articles for article (PubMed ID: 21264819)
1. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
[TBL] [Abstract][Full Text] [Related]
2. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas.
Kimura T; Suzuki H; Ohashi T; Asano K; Kiyota H; Eto Y
Cancer; 2001 Nov; 92(10):2555-61. PubMed ID: 11745189
[TBL] [Abstract][Full Text] [Related]
3. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.
van Rhijn BW; van Tilborg AA; Lurkin I; Bonaventure J; de Vries A; Thiery JP; van der Kwast TH; Zwarthoff EC; Radvanyi F
Eur J Hum Genet; 2002 Dec; 10(12):819-24. PubMed ID: 12461689
[TBL] [Abstract][Full Text] [Related]
4. Mutations of fibroblast growth factor receptor 3 gene (FGFR3) in transitional cell carcinoma of urinary bladder in Thai patients [Revision-2a].
Jantip J; Tanthanuch M; Kanngurn S; Karnchanawanichkul W; Pripatnanont C; Sangkhathat S; Thongsuksai P
J Med Assoc Thai; 2013 Aug; 96(8):976-83. PubMed ID: 23991606
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.
Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Amorós A; Tardón A; Carrato A; Serra C; Malats N; Real FX
J Clin Oncol; 2006 Aug; 24(22):3664-71. PubMed ID: 16877735
[TBL] [Abstract][Full Text] [Related]
6. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.
Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Jaramillo R; Amorós A; Tardón A; García-Closas R; Serra C; Carrato A; Malats N; Real FX
Clin Cancer Res; 2005 Aug; 11(15):5444-50. PubMed ID: 16061860
[TBL] [Abstract][Full Text] [Related]
7. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma.
Sibley K; Cuthbert-Heavens D; Knowles MA
Oncogene; 2001 Feb; 20(6):686-91. PubMed ID: 11314002
[TBL] [Abstract][Full Text] [Related]
8. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
9. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.
Billerey C; Chopin D; Aubriot-Lorton MH; Ricol D; Gil Diez de Medina S; Van Rhijn B; Bralet MP; Lefrere-Belda MA; Lahaye JB; Abbou CC; Bonaventure J; Zafrani ES; van der Kwast T; Thiery JP; Radvanyi F
Am J Pathol; 2001 Jun; 158(6):1955-9. PubMed ID: 11395371
[TBL] [Abstract][Full Text] [Related]
10. Frequent FGFR3 mutations in urothelial papilloma.
van Rhijn BW; Montironi R; Zwarthoff EC; Jöbsis AC; van der Kwast TH
J Pathol; 2002 Oct; 198(2):245-51. PubMed ID: 12237885
[TBL] [Abstract][Full Text] [Related]
11. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.
Bakkar AA; Wallerand H; Radvanyi F; Lahaye JB; Pissard S; Lecerf L; Kouyoumdjian JC; Abbou CC; Pairon JC; Jaurand MC; Thiery JP; Chopin DK; de Medina SG
Cancer Res; 2003 Dec; 63(23):8108-12. PubMed ID: 14678961
[TBL] [Abstract][Full Text] [Related]
12. FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.
Bodoor K; Ghabkari A; Jaradat Z; Alkhateeb A; Jaradat S; Al-Ghazo MA; Matalka I; Musleh H; Haddad Y
Cancer Epidemiol; 2010 Dec; 34(6):724-32. PubMed ID: 20542753
[TBL] [Abstract][Full Text] [Related]
13. Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix.
Wu R; Connolly D; Ngelangel C; Bosch FX; Muñoz N; Cho KR
Oncogene; 2000 Nov; 19(48):5543-6. PubMed ID: 11114733
[TBL] [Abstract][Full Text] [Related]
14. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
van Oers JM; Zwarthoff EC; Rehman I; Azzouzi AR; Cussenot O; Meuth M; Hamdy FC; Catto JW
Eur Urol; 2009 Mar; 55(3):650-7. PubMed ID: 18584939
[TBL] [Abstract][Full Text] [Related]
15. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection.
Rieger-Christ KM; Mourtzinos A; Lee PJ; Zagha RM; Cain J; Silverman M; Libertino JA; Summerhayes IC
Cancer; 2003 Aug; 98(4):737-44. PubMed ID: 12910517
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer.
Miyake M; Sugano K; Sugino H; Imai K; Matsumoto E; Maeda K; Fukuzono S; Ichikawa H; Kawashima K; Hirabayashi K; Kodama T; Fujimoto H; Kakizoe T; Kanai Y; Fujimoto K; Hirao Y
Cancer Sci; 2010 Jan; 101(1):250-8. PubMed ID: 19843069
[TBL] [Abstract][Full Text] [Related]
17. Activation of RAS family genes in urothelial carcinoma.
Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
[TBL] [Abstract][Full Text] [Related]
18. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
[TBL] [Abstract][Full Text] [Related]
19. Specific p53 gene mutations in urinary bladder epithelium after the Chernobyl accident.
Yamamoto S; Romanenko A; Wei M; Masuda C; Zaparin W; Vinnichenko W; Vozianov A; Lee CC; Morimura K; Wanibuchi H; Tada M; Fukushima S
Cancer Res; 1999 Aug; 59(15):3606-9. PubMed ID: 10446970
[TBL] [Abstract][Full Text] [Related]
20. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.
Jebar AH; Hurst CD; Tomlinson DC; Johnston C; Taylor CF; Knowles MA
Oncogene; 2005 Aug; 24(33):5218-25. PubMed ID: 15897885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
